Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.74 |
| ▸ | STAT1 | P42224 | 1/20 | 0.74 |
| ▸ | TOP1 | P11387 | 4/20 | 0.43 |
| ▸ | CYCS | P99999 | 3/20 | 0.42 |
| ▸ | TERT | O14746 | 4/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2940532 | 1.00 | STAT3 (0.74) | STAT3STAT1TOP1CYCSTERT | |
| SCHEMBL5134031 | 1.00 | STAT3 (0.74) | STAT3STAT1TOP1CYCSTERT | |
| SCHEMBL30767176 | 1.00 | STAT3 (0.74) | STAT3STAT1TOP1CYCSTERT | |
| SCHEMBL5134266 | 0.99 | STAT3 (0.72) | STAT3STAT1TOP1CYCSTERT | |
| SCHEMBL5013665 | 0.96 | STAT3 (0.71) | STAT3STAT1TOP1CYCSTERT | |
| SCHEMBL30293296 | 0.92 | STAT3 (0.86) | STAT3STAT1TOP1CYCSTERT | |
| SCHEMBL31550992 | 0.92 | STAT3 (0.86) | STAT3STAT1TOP1CYCSTERT | |
| SCHEMBL1224432 | 0.92 | STAT3 (0.86) | STAT3STAT1TOP1CYCSTERT | |
| SCHEMBL31324939 | 0.91 | STAT3 (0.84) | STAT3STAT1TOP1CYCSTERT | |
| SCHEMBL31324940 | 0.91 | STAT3 (0.84) | STAT3STAT1TOP1CYCSTERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110730782-B | Photodynamic therapy compounds and photodynamic therapy methods | 光盐生物科技有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-11147797-B2 | Photodynamic therapeutic compounds and photodynamic methods of treatment | SALT AND LIGHT PHARMACEUTICALS PTY. LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| CN-110730782-A | Photodynamic therapy compounds and methods of photodynamic therapy | 光盐生物科技有限公司 | 2020-01-24 | — | — | CN | disclosed |
| WO-2018102849-A9 | PHOTODYNAMIC THERAPEUTIC COMPOUNDS AND PHOTODYNAMIC METHODS OF TREATMENT | SALT AND LIGHT PHARMACEUTICALS PTY. LTD. (AU) | 2019-11-28 | — | — | WO | disclosed |
| US-20190307725-A1 | PHOTODYNAMIC THERAPEUTIC COMPOUNDS AND PHOTODYNAMIC METHODS OF TREATMENT | SALT AND LIGHT PHARMACEUTICALS PTY. LTD. (AU) | 2019-10-10 | — | — | US | disclosed |
| EP-3548494-A1 | PHOTODYNAMIC THERAPEUTIC COMPOUNDS AND PHOTODYNAMIC METHODS OF TREATMENT | Salt and Light Pharmaceuticals Pty. Ltd. (AU) | 2019-10-09 | — | — | EP | disclosed |
| EP-3005387-B1 | PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR CELL | RICOH CO LTD (JP) | 2019-04-03 | — | — | EP | disclosed |
| WO-2018102849-A1 | PHOTODYNAMIC THERAPEUTIC COMPOUNDS AND PHOTODYNAMIC METHODS OF TREATMENT | SALT AND LIGHT PHARMACEUTICALS PTY. LTD. (AU) | 2018-06-14 | — | — | WO | disclosed |
| US-9640330-B2 | Photoelectric conversion element and solar cell | RICOH COMPANY, LTD. (JP) | 2017-05-02 | — | — | US | disclosed |
| US-20160126021-A1 | PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR CELL | RICOH COMPANY, LTD. (JP) | 2016-05-05 | — | — | US | disclosed |
| EP-3005387-A1 | PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR CELL | Ricoh Company, Ltd. (JP) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014196659-A1 | PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR CELL | RICOH COMPANY, LTD. (JP) | 2014-12-11 | — | — | WO | disclosed |
| US-7417142-B2 | Chiral porphyrins, chiral metalloporphyrins, and methods for synthesis of the same | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-20060030718-A1 | Cobalt-based catalysts for the cyclization of alkenes | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-02-09 | — | — | US | disclosed |
| US-6951935-B2 | Heteroatom-substituted porphyrins and methods for synthesis of same | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050124596-A1 | Chiral porphyrins, chiral metalloporphyrins, and methods for synthesis of the same | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2005-06-09 | — | — | US | disclosed |
| US-20030236400-A1 | Heteroatom-substituted porphyrins and methods for synthesis of same | UNIVERSITY OF TENNESSEE RESEARCH CORPORATION | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030718-A1 | Cobalt-based catalysts for the cyclization of alkenes | PPOX, HCCS, ICOSLG | STAT3 3817/4885STAT1 4312/4885TOP1 1268/4885 |
| US-20030236400-A1 | Heteroatom-substituted porphyrins and methods for synthesis of same | PPOX, HMBS, UROD | STAT3 4156/4885STAT1 3973/4885TOP1 3026/4885 |
| US-20190307725-A1 | PHOTODYNAMIC THERAPEUTIC COMPOUNDS AND PHOTODYNAMIC METHODS OF TREATMENT | PPOX, QDPR, ALDH1A2 | STAT3 115/4885STAT1 270/4885TOP1 1742/4885 |
| US-11147797-B2 | Photodynamic therapeutic compounds and photodynamic methods of treatment | PPOX, QDPR, ALDH1A2 | STAT3 115/4885STAT1 270/4885TOP1 1742/4885 |
| US-20050124596-A1 | Chiral porphyrins, chiral metalloporphyrins, and methods for synthesis of the same | PPOX, PPIF, HMBS | STAT3 2986/4885STAT1 3579/4885TOP1 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.